Eli Lilly bets big on late-stage Alzheimer’s drugs

Alzheimer's has long been one of the most difficult and confusing targets in drug development. But lured by the prospect of mega-blockbuster revenue for any new drug that alleviates key symptoms of the memory-wasting disease, Eli Lilly has wagered heavily on two late-stage programs, with more therapies being tested further down the pipeline. Barclays' Tony Butler told Bloomberg that a drug that demonstrates an ability to reduce memory loss should be able to garner $5 billion in annual sales....